Can Gut-Derived SCFAs Help Lower Blood Pressure?

Prebiotic fiber may help lower blood pressure in people who already have hypertension, but the best estimate comes from only three randomized trials. In that subgroup, a 2025 meta-analysis found average reductions of 8.5 mmHg in systolic pressure and 5.2 mmHg in diastolic pressure. Those numbers matter clinically. They also need replication before anyone treats inulin or resistant starch as a substitute for antihypertensive medication.

The interesting part is the proposed route: fiber reaches the colon, gut microbes ferment it, and the resulting short-chain fatty acids (SCFAs) may influence blood vessels, inflammation, the kidneys, and the renin-angiotensin system. This is more specific than the familiar instruction to eat more fiber. It is still not a license to turn your home blood-pressure cuff into a microbiome oracle.

The signal appears in hypertension, not across every population

A 2025 systematic review and meta-analysis pooled six randomized controlled trials of prebiotic supplementation and blood pressure. Across all participants, prebiotics reduced systolic blood pressure by 4.5 mmHg (95% CI, −9.3 to 0.3; p=0.07) and diastolic pressure by 2.5 mmHg (95% CI, −5.4 to 0.4; p=0.09). Neither pooled result reached conventional statistical significance.

The pooled analysis also had high heterogeneity, about 80%. That means the trials did not tell one consistent story, which is unsurprising: they enrolled different populations and used different fibers, doses, and intervention lengths. Combining unlike studies can produce a tidy-looking average that answers no one's practical question.

The more encouraging result came from the review's prespecified subgroup of three trials in people with hypertension. Prebiotics lowered systolic pressure by 8.5 mmHg (95% CI, −13.9 to −3.1; p=0.002) and diastolic pressure by 5.2 mmHg (95% CI, −8.5 to −2.0; p=0.002). Heterogeneity fell to about 46%, and the review's meta-regression identified hypertensive status as the main source of variation among trial results.

This does not show that fermentable fiber lowers pressure in everyone, or that it can replace drugs. Two metabolic-syndrome trials in the same review found no significant blood-pressure benefit. In those studies, blood pressure was a secondary outcome and control groups received guideline-based dietary interventions, which may have made an additional fiber effect harder to detect. Biological differences may matter, too: the pathway may have more room to move when hypertension is established.

How fiber could reach the blood-pressure system

Humans do not digest many fermentable fibers in the small intestine. Colonic anaerobes do the job instead, producing acetate, propionate, and butyrate. The meta-analysis describes enrichment of taxa associated with SCFA production, including members of the Lachnospiraceae and Ruminococcaceae families, as well as Bifidobacterium and Akkermansia after inulin-type interventions. Plasma butyrate increased in three of the six included human trials.

SCFAs can signal through G-protein-coupled receptors called GPR41 and GPR43, which are expressed in gut tissue, kidney tubules, and vascular endothelium. The proposed consequences include changes in vascular tone, renal sodium handling, immune activity, and renin-angiotensin signaling. Butyrate may also support the intestinal barrier and reduce inflammatory signaling; acetate and propionate may affect peripheral resistance and renin-angiotensin pathways.

Those receptor-level details are biologically plausible, but the direct evidence is mainly preclinical. Animal and cell studies support GPR41/GPR43 signaling, regulatory T-cell effects, and renal mechanisms. Human randomized trials have not separated how much of the observed blood-pressure change comes from each route. A mechanism can be coherent without being fully mapped in people.

Animal fecal-transplant work adds a causal clue, not a human verdict. In the evidence reviewed by Msdi et al., transplanting microbiota from hypertensive donors into germ-free mice produced dysbiosis and higher blood pressure. That supports the idea that microbiome changes can sit upstream of hypertension in a mouse model. It does not establish that human fecal transplantation would prevent or treat hypertension.

Human biomarkers point in the same direction, with limits

A 2024 cross-sectional study in an elderly Chinese population found that circulating SCFA concentrations were inversely associated with blood-pressure measures. This is useful because it shows that the microbial metabolites are measurable in peripheral blood and track with pressure outside an intervention trial. It cannot prove that SCFAs caused the lower readings. Diet quality, physical activity, medications, illness, and other differences between participants could contribute to both.

The pharmacology connection is also intriguing. A 2025 systematic review of ACE inhibitors and ARBs reports that Bifidobacterium bifidum has direct ACE-inhibitory activity and that these common antihypertensive drug classes can alter gut-microbiome composition. ACE is a target of first-line blood-pressure drugs, so the microbiome may interact with familiar cardiovascular biology rather than operate in a separate nutritional universe. The review does not provide a blood-pressure effect size attributable to B. bifidum, so this is mechanistic context, not proof of treatment efficacy.

Which fibers have shown a prebiotic effect?

The blood-pressure meta-analysis does not identify one optimal fiber, dose, or duration. Still, randomized trials show that ordinary food-derived or supplemental fermentable fibers can shift the microbial environment in the expected direction.

In a 45-day randomized trial, Xu and colleagues compared 80 g daily of oats with rice in 210 mildly hypercholesterolemic Chinese adults. Oats increased Akkermansia muciniphila, Roseburia, and SCFA-related measures relative to rice; the trial focused on lipids rather than blood pressure. It supports the pathway, not a claim that oats lower blood pressure in this population.

Likewise, a double-blind, placebo-controlled trial of resistant potato starch found that 3.5 g or 7 g daily for four weeks produced prebiotic effects. At 3.5 g daily, participants had greater changes in Bifidobacterium and Akkermansia than placebo recipients, along with fewer diarrhea- and constipation-associated bowel movements. The study did not establish a blood-pressure effect.

A separate 2025 placebo-controlled trial in overweight adults tested a slowly fermentable fiber mixture against a high-protein dietary background, with insulin sensitivity and metabolic health as its main outcomes. That study adds to evidence that fermentable fiber can alter SCFA-producing taxa, while also illustrating why fiber trials cannot be assumed to have interchangeable cardiovascular results. Its population and endpoints were not designed to test hypertension.

Why the evidence has not become a prescription

Most participants in the blood-pressure trials were taking antihypertensive medication. The observed benefit therefore appears additive to background care, but the independent effect of prebiotic fiber in drug-naive people with treatment-eligible hypertension remains unknown. Publication bias also cannot be excluded: Egger's test was borderline at p=0.07, and six trials are too few for a reliable funnel-plot judgment.

Longer studies do exist, but they do not solve the dosing question. A 12-month randomized study of 84 patients with hypertension tested combinations of standard drug therapy, a fiber-enriched balanced diet, prebiotic supplementation, and physical-therapy courses. It examined blood-pressure control, microbiota composition, and inflammatory markers, but the available abstract does not provide extractable blood-pressure effect sizes. Its multi-part intervention also cannot isolate fiber's contribution.

The current evidence supports a restrained conclusion: highly fermentable fiber can shift gut bacteria and SCFA-related biology, and prebiotic supplementation has a statistically significant blood-pressure signal in a small hypertensive subgroup. It does not yet support a precise daily target, a preferred supplement, or withdrawal of medication.

For someone with hypertension, fermentable-fiber foods and supplements are reasonable adjuncts to discuss with a clinician—especially alongside regular home blood-pressure monitoring. Increase intake gradually if you are prone to gas or bowel changes, and judge the intervention by repeated readings, not by how virtuous your grocery cart looks.

The next useful trial is straightforward: enroll enough people with hypertension, make blood pressure the primary endpoint, standardize fiber type and dose, follow participants for at least six months, and separate results by medication status. Until then, the SCFA story is promising physiology with a small but clinically interesting human signal.